DE-T1と体外受精(IVF)：適切な投与期間が出生率を向上させる？ 英ウィメンズクリニックの報告

DE-T1と体外受精(IVF)

妊娠を望むカップルにとって、体外受精（IVF）は一つの希望をもたらします。IVFは、卵子と精子を人工的に受精させ、胚を形成し、その胚を母親の子宮に戻す技術です。しかし、この治療法は成功率が必ずしも高いわけではなく、特に高齢の女性ではさらに困難になります。ここでは、最近の研究で明らかになった、Shawkea DE-T1という栄養補助食品がIVFの成功率を向上させる可能性について紹介します。

DE-T1って何？

Shawkea DE-T1は、漢方薬の一種であり、体外受精(IVF)治療を受ける女性に対する補助食品として用いられています。この補助食品は、妊娠を望む女性の胚の質を改善することを目指しています。

DE-T1の効果についての研究

兵庫県の英ウィメンズクリニックで行われた最近の研究では、DE-T1が体外受精(IVF)の成果にどのように影響するかを調査しました。研究の対象は、30歳以上で体外受精(IVF)を試みた1014人の女性で、これらの女性はDE-T1を使用したかどうかで2つのグループに分けられました。1つはDE-T1投与群（712人）で、もう1つは対照群（302人）です。

さて、この場で少し「胚盤胞取得率」という言葉について説明します。これは、体外受精による胚培養で少なくとも1つの胚盤胞を生産した患者の割合を意味します。胚盤胞とは、受精卵が成長し、約5日後に形成される段階のことを指します。つまり、この胚盤胞取得率が高ければ高いほど、体外受精(IVF)の成功率も上がると考えられます。

この研究では、DE-T1投与群と対照群での胚盤胞取得率を比較しました。そしてその結果、DE-T1の使用により胚盤胞取得率が大幅に向上したことがわかりました。特に、1～3ヶ月および4～6ヶ月のShawkea DE-T1投与期間では、投与群の胚盤胞取得率が対照群と比較して高かったのです。具体的には、1～3ヶ月の投与では83.27%対55.31%、4～6ヶ月の投与では69.44%対44.44%と、DE-T1投与群の方が有意に高い結果となりました。

年齢との関係

さらに興味深いことに、患者の年齢が上がるにつれて、DE-T1の効果がさらに顕著になることが見出されました。例えば、30歳以上35歳未満の女性のうち、65.25%がDE-T1の1～3ヶ月の投与後に胚盤胞を取得しました。これに対し、43歳以上の女性では、同じ投与期間での胚盤胞取得率は19.75%と低下しました。

しかし、これはDE-T1が高齢の女性には効果がないというわけではありません。実際、高齢の女性では、DE-T1の投与期間を適切に延長することで、より良い結果が得られました。

結論

妊娠を望む女性、特に体外受精(IVF)治療を考えている方々にとって、DE-T1は一つの有望な選択肢といえます。その投与期間と効果については、年齢と共に調整することが重要であり、高齢の女性でも適切な期間を経てDE-T1を使用すれば、体外受精(IVF)の成功率を高める可能性があります。

参考文献

URL: https://www.researchgate.net/publication/362483524_Effect_of_different_durations_of_Shawkea_DE-T1_administration_on_blastocyst_obtained_rate_in_women_receiving_IVF-ET_treatment_A_secondary_analysis_of_a_cohort_study
TITLE: Effect of different durations of Shawkea DE-T1 ... - ResearchGate
CONTENT: Objective To explore the appropriate duration of Shawkea DE-T1 use, and to provide a basis for the optimization of the Shawkea DE-T1 administration duration for different women. Methods Based on a previous retrospective cohort study, 1,014 patients aged ≥ 30 years who used in vitro fertilization (IVF) for conception at Hanabusa Women’s Clinic, Kobe, Japan, were included in this secondary analysis and were allocated to an Shawkea DE-T1-administration group (n = 712) and a control group (n = 302) based on their use of Shawkea DE-T1. All patients in the two groups received interventions following the guidelines of the Japanese Institution for Standardizing Assisted Reproductive Technology Intervention, and patients in the administration group were provided Shawkea DE-T1 as recommended by the Nutritional Supplement Support Center of Hanabusa Womens Clinic. The blastocyst obtained rate (percentage of patients who produced at least one blastocyst upon in vitro embryo culture relative to all patients in the same group) was compared between the two groups of patients following treatment durations of 1–3 months, 4–6 months, and > 6 months. Analysis was performed on the actual duration of Shawkea DE-T1 administration for all patients who achieved blastocyst in vitro according to their age level (≥ 30 and < 35 years of age; ≥35 and < 40 years; ≥40 and < 43 years; and ≥ 43 years of age). Results After a Shawkea DE-T1 administration of 1–3 months or 4–6 months, the blastocyst obtained rates in the administration group were significantly higher than those of the control group (83.27% vs. 55.31% for 1–3 months, P = 1.02×10 − 10 ; 69.44% vs. 44.44% for 4–6 months, P = 4.70×10 − 4 ), while no significant difference was uncovered between the two groups with > 6 months of administration (73.35% vs. 72.46%, P = 0.76). Analysis of the treatment duration of patients at different age levels who produced blastocysts showed that the treatment duration increased commensurate with patient age: i.e., 65.25% of women ≥ 30 and < 35 years of age achieved blastocyst after a Shawkea DE-T1 administration of 1–3 months; while only 19.75% of women ≥ 43 years of age successfully achieved in vitro development of embryos to blastocyst stage with a Shawkea DE-T1 administration of 1–3 months. Conclusion Shawkea DE-T1 use for 1–3 months and 3–6 months significantly improved the blastocyst obtained rate in women receiving IVF treatment. Appropriate extension of Shawkea DE-T1 administration duration also achieved a better effect in women of advanced reproductive age. To read the file of this research, you can request a copy directly from the authors.ResearchGate

URL: https://www.researchsquare.com/article/rs-1905199/v1
TITLE: Effect of different durations of Shawkea DE-T1 ... - Research Square
CONTENT: https://doi.org/10.21203/rs.3.rs-1905199/v1This work is licensed under a CC BY 4.0 LicenseVersion 1posted 04 Aug, 2022You are reading this latest preprint versionObjective To explore the appropriate duration of Shawkea DE-T1 use, and to provide a basis for the optimization of the Shawkea DE-T1 administration duration for different women.Methods Based on a previous retrospective cohort study, 1,014 patients aged ≥ 30 years who used in vitro fertilization (IVF) for conception at Hanabusa Women’s Clinic, Kobe, Japan, were included in this secondary analysis and were allocated to an Shawkea DE-T1-administration group (n = 712) and a control group (n = 302) based on their use of Shawkea DE-T1. All patients in the two groups received interventions following the guidelines of the Japanese Institution for Standardizing Assisted Reproductive Technology Intervention, and patients in the administration group were provided Shawkea DE-T1 as recommended by the Nutritional Supplement Support Center of Hanabusa Womens Clinic. The blastocyst obtained rate (percentage of patients who produced at least one blastocyst upon in vitro embryo culture relative to all patients in the same group) was compared between the two groups of patients following treatment durations of 1–3 months, 4–6 months, and > 6 months. Analysis was performed on the actual duration of Shawkea DE-T1 administration for all patients who achieved blastocyst in vitro according to their age level (≥ 30 and < 35 years of age; ≥35 and < 40 years; ≥40 and < 43 years; and ≥ 43 years of age).Results After a Shawkea DE-T1 administration of 1–3 months or 4–6 months, the blastocyst obtained rates in the administration group were significantly higher than those of the control group (83.27% vs. 55.31% for 1–3 months, P = 1.02×10− 10; 69.44% vs. 44.44% for 4–6 months, P = 4.70×10− 4), while no significant difference was uncovered between the two groups with > 6 months of administration (73.35% vs. 72.46%, P = 0.76). Analysis of the treatment duration of patients at different age levels who produced blastocysts showed that the treatment duration increased commensurate with patient age: i.e., 65.25% of women ≥ 30 and < 35 years of age achieved blastocyst after a Shawkea DE-T1 administration of 1–3 months; while only 19.75% of women ≥ 43 years of age successfully achieved in vitro development of embryos to blastocyst stage with a Shawkea DE-T1 administration of 1–3 months.Conclusion Shawkea DE-T1 use for 1–3 months and 3–6 months significantly improved the blastocyst obtained rate in women receiving IVF treatment. Appropriate extension of Shawkea DE-T1 administration duration also achiev

URL: https://europepmc.org/article/PPR/PPR528077
TITLE: Effect of different durations of Shawkea DE-T1 administration on ...
CONTENT: Sign in | Create an account
https://orcid.org